2017
Cognition and the course of prodromal Parkinson's disease
Weintraub D, Chahine LM, Hawkins KA, Siderowf A, Eberly S, Oakes D, Seibyl J, Stern MB, Marek K, Jennings D, Investigators T. Cognition and the course of prodromal Parkinson's disease. Movement Disorders 2017, 32: 1640-1645. PMID: 29063713, PMCID: PMC5722226, DOI: 10.1002/mds.27189.Peer-Reviewed Original ResearchConceptsSpeed/attentionCognitive declineProdromal participantsBaseline neuropsychological test performanceExecutive function/Role of cognitionNeuropsychological test performanceFuture cognitive declineBaseline cognitive scoresCognitive domainsGlobal cognitionBaseline cognitionCognitive scoresCognitionTest performanceFuture declinePD-convertersDopamine systemHyposmic individualsProdromal PDLongitudinal changesFunction/ParticipantsDopamine transporter bindingIndividuals
2012
The course of cognitive functioning over six months in individuals at clinical high risk for psychosis
Barbato M, Colijn MA, Keefe RS, Perkins DO, Woods SW, Hawkins KA, Christensen BK, Addington J. The course of cognitive functioning over six months in individuals at clinical high risk for psychosis. Psychiatry Research 2012, 206: 195-199. PMID: 23159196, PMCID: PMC3600156, DOI: 10.1016/j.psychres.2012.10.013.Peer-Reviewed Original ResearchConceptsClinical high riskCHR individualsComprehensive cognitive test batteryCognitive test batteryCognitive impairmentFuture longitudinal researchCognitive functioningCognitive performanceCognitive testsTest batteryLongitudinal researchCognitionPoor performanceLongitudinal changesPsychosisIndividualsParticipantsImpairmentBaseline participantsFunctioningPerformanceBatteriesResearchProdromeGlycine treatment of the risk syndrome for psychosis: Report of two pilot studies
Woods SW, Walsh BC, Hawkins KA, Miller TJ, Saksa JR, D'Souza DC, Pearlson GD, Javitt DC, McGlashan TH, Krystal JH. Glycine treatment of the risk syndrome for psychosis: Report of two pilot studies. European Neuropsychopharmacology 2012, 23: 931-940. PMID: 23089076, PMCID: PMC4028140, DOI: 10.1016/j.euroneuro.2012.09.008.Peer-Reviewed Original ResearchConceptsPilot studyRisk syndromeSyndrome patientsNegative symptomsShort-term pilot studyEffect sizeAdjunctive antipsychotic medicationOpen-label studyPatients meeting criteriaNMDA receptor functionDurability of effectPsychosis risk symptomsGlycine site agonistsGroup effect sizesWeeks of evaluationAntipsychotic medicationSyndrome subjectsPromising effect sizesTreatment needsLarge effect sizesMeeting criteriaCognitive impairmentReduced symptomsReceptor functionSymptoms